EA
ANIP icon

Ellsworth Advisors’s ANI Pharmaceuticals ANIP Stock Holding History

Ellsworth Advisors’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$801K Buy
9,914
+396
+4% +$31.8K 0.13% 132
2026
Q1 		$732K Buy
9,518
+1,899
+25% +$148K 0.14% 129
2025
Q4 		$650K Buy
+7,619
New +$660K 0.13% 134

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ellsworth Advisors's ANIP Position: Q2 2026 in Review

Ellsworth Advisors increased its ANI Pharmaceuticals (ANIP) stake by 4.2% in Q2 2026, buying an estimated $31.8K and bringing the position to 9,914 shares worth $801K. The position accounts for 0.13% of the portfolio, ranked #132.

Ellsworth Advisors first reported a position in ANIP in Q4 2025 and has held it in 3 quarters since. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Ellsworth Advisors held 9,914 shares of ANI Pharmaceuticals worth $801K as of Q2 2026.
  • Ellsworth Advisors bought 396 ANI Pharmaceuticals shares in Q2 2026, an estimated $31.8K.
  • ANI Pharmaceuticals made up 0.13% of Ellsworth Advisors's portfolio in Q2 2026, its #132 holding.
  • Ellsworth Advisors first reported a position in ANI Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Ellsworth Advisors's 13F filing for Q2 2026, filed 16 Jul 2026.